Baseline Cerebral Small Vessel Disease Predicting Long‐Term Cognitive Decline in Transient Ischemic Attack Patients
Open Access
- 26 March 2026
- journal article
- Published by Wiley in European Journal of Neurology
- Vol. 33 (4) , e70578
Abstract
Background: Cerebral small vessel disease (CSVD) is a common incidental MRI finding in patients with transient ischemic attack (TIA) and stroke and has been linked to cognitive decline. This study investigated the prevalence of CSVD imaging biomarkers in TIA patients and their association with cognitive performance over 3 years. Methods: We included 246 TIA patients from the INSPiRE‐TMS study ( ClinicalTrials.gov : NCT01586702). CSVD was assessed on baseline 3 T MRI using a composite score (0–4) including white matter hyperintensities (WMH), lacunes, cerebral microbleeds (CMBs), and enlarged perivascular spaces (PVS). Cognitive performance was evaluated using the Montreal Cognitive Assessment (MoCA) at baseline and annually for 3 years. Results: At least one CSVD imaging biomarker was present in 58.5% of patients. Lacunes (36.6%) were the most common, followed by PVS (28.1%), WMH (19.5%), and CMBs (17.9%). Higher CSVD‐score was independently associated with greater cognitive decline over 3 years ( β = −0.52, 95% CI −0.95– −0.08, p = 0.020), along with older age ( β = −0.08, 95% CI −0.13 to −0.03, p = 0.001). CMB burden was the strongest predictive component of the CSVD‐score ( β = 0.42, 95% CI −0.63 to −0.22, p < 0.001). CSVD‐score was particularly associated with decline in the memory domain (adjusted β of −0.18, 95% CI −0.32 to −0.04, p = 0.015). Conclusion: CSVD imaging markers are present in over half of TIA patients and are independently associated with cognitive decline up to 3 years, with the strongest effect on memory . Whether the presence of CMBs is the strongest predictive imaging biomarker of cognitive decline in TIA patients requires confirmation in further studies.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01EW2302)
- Pfizer
This publication has 49 references indexed in Scilit:
- Is the difference real, is the difference relevant: the minimal detectable and clinically important changes in the Montreal Cognitive AssessmentCerebral Circulation - Cognition and Behavior, 2024
- The Montreal Cognitive Assessment: Norms and Reliable Change Indices for Standard and MoCA-22 AdministrationsArchives of Clinical Neuropsychology, 2024
- Accuracy of the Montreal Cognitive Assessment tool for detecting mild cognitive impairment: A systematic review and meta‐analysisAlzheimer's & Dementia, 2023
- Vascular Cognitive Impairment and DementiaJACC, 2019
- Delayed‐onset dementia after stroke or transient ischemic attackAlzheimer's & Dementia, 2016
- Stroke injury, cognitive impairment and vascular dementiaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2016
- Longitudinal Change in Performance on the Montreal Cognitive Assessment in Older AdultsThe Clinical Neuropsychologist, 2015
- The Diagnosis and Management of Mild Cognitive ImpairmentJAMA, 2014
- Cerebral microbleeds and cognition in cerebrovascular disease: An updateJournal of the Neurological Sciences, 2012
- Cognitive dysfunction in patients with cerebral microbleeds on T2*-weighted gradient-echo MRIBrain, 2004